Table 1.
Baseline characteristics by transplant status and renal function in patients receiving induction with RVd.
| Transplanted (n = 344) | Non-transplanted (n = 289) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline renal function | Normal n = 212 | Mild n = 88 | Moderate n = 33 | Severe n = 11 | Overall n = 344 | Normal n = 118 | Mild n = 93 | Moderate n = 53 | Severe n = 25 | Overall n = 289 |
| Median age, years (range) | 58 (24.0–73.0) | 63 (38.0–75.0) | 60 (42.0–75.0) | 61 (37.0–70.0) | 59 (24.0–75.0) | 61 (35.0–80.0) | 71 (46.0–90.0) | 72 (52.0–88.0) | 70 (51.0–89.0) | 69 (35.0–90.0) |
| Male, n (%) | 132 (62.3) | 50 (56.8) | 20 (60.6) | 7 (63.6) | 209 (60.8) | 81 (68.6) | 50 (53.8) | 26 (49.1) | 11 (44.0) | 168 (58.1) |
| Race, n (%) | ||||||||||
| White | 181 (85.4) | 82 (93.2) | 28 (84.8) | 6 (54.5) | 297 (86.3) | 98 (83.1) | 73 (78.5) | 44 (83.0) | 18 (72.0) | 233 (80.6) |
| Black | 27 (12.7) | 6 (6.8) | 4 (12.1) | 4 (36.4) | 41 (11.9) | 15 (12.7) | 16 (17.2) | 6 (11.3) | 5 (20.0) | 42 (14.5) |
| Othera | 4 (1.9) | 0 | 1 (3.0) | 1 (9.1) | 6 (1.7) | 5 (4.2) | 4 (4.3) | 3 (5.7) | 2 (8.0) | 14 (4.8) |
| ECOG PS, n (%) | ||||||||||
| 0–1 | 132 (62.3) | 52 (59.1) | 23 (69.7) | 3 (27.3) | 210 (61.0) | 76 (64.4) | 52 (55.9) | 26 (49.1) | 11 (44.0) | 165 (57.1) |
| 2–3 | 16 (7.5) | 4 (4.5) | 1 (3.0) | 2 (18.2) | 23 (6.7) | 13 (11.0) | 7 (7.5) | 4 (7.5) | 2 (8.0) | 26 (9) |
| Calculated ISS stage, n (%) | ||||||||||
| I | 69 (32.5) | 23 (26.1) | 2 (6.1) | 0 | 94 (27.3) | 23 (19.5) | 13 (14.0) | 5 (9.4) | 0 | 41 (14.2) |
| II | 63 (29.7) | 22 (25.0) | 8 (24.2) | 2 (18.2) | 95 (27.6) | 41 (34.7) | 29 (31.2) | 11 (20.8) | 3 (12.0) | 84 (29.1) |
| III | 28 (13.2) | 17 (19.3) | 14 (42.4) | 7 (63.6) | 66 (19.2) | 16 (13.6) | 23 (24.7) | 20 (37.7) | 17 (68.0) | 76 (26.3) |
| Calcium ≥ 11.5 mg/dL, n (%) | 12 (5.7) | 8 (9.1) | 5 (15.2) | 2 (18.2) | 27 (7.8) | 6 (5.1) | 11 (11.8) | 9 (17.0) | 4 (16.0) | 30 (10.4) |
| Hb <10 or >2 g/dL less than LLN, n (%) | 71 (33.5) | 38 (43.2) | 21 (63.6) | 8 (72.7) | 138 (40.1) | 50 (42.4) | 40 (43.0) | 34 (64.2) | 24 (96.0) | 148 (51.2) |
| Del(17p), n (%) | ||||||||||
| Yes | 36 (17.0) | 13 (14.8) | 1 (3.0) | 2 (18.2) | 52 (15.1) | 13 (11.0) | 12 (12.9) | 5 (9.4) | 2 (8.0) | 32 (11.1) |
| No | 139 (65.6) | 61 (69.3) | 22 (66.7) | 6 (54.5) | 228 (66.3) | 74 (62.7) | 57 (61.3) | 32 (60.4) | 15 (60.0) | 178 (61.6) |
| Data not available | 37 (17.5) | 14 (15.9) | 10 (30.3) | 3 (27.3) | 64 (18.6) | 31 (26.3) | 24 (25.8) | 16 (30.2) | 8 (32.0) | 79 (27.3) |
| +1q21, n (%) | ||||||||||
| Yes | 12 (5.7) | 4 (4.5) | 5 (15.2) | 2 (18.2) | 23 (6.7) | 6 (5.1) | 9 (9.7) | 6 (11.3) | 1 (4.0) | 22 (7.6) |
| No | 91 (42.9) | 42 (47.7) | 12 (36.4) | 3 (27.3) | 148 (43.0) | 45 (38.1) | 34 (36.6) | 22 (41.5) | 10 (40.0) | 111 (38.4) |
| Data not available | 109 (51.4) | 42 (47.7) | 16 (48.5) | 6 (54.5) | 173 (50.3) | 67 (56.8) | 50 (53.8) | 25 (47.2) | 14 (56.0) | 156 (54.0) |
| 1 P loss, n (%) | ||||||||||
| Yes | 3 (1.4) | 3 (3.4) | 0 | 0 | 6 (1.7) | 1 (0.8) | 2 (2.2) | 2 (3.8) | 1 (4.0) | 6 (2.1) |
| No | 14 (6.6) | 10 (11.4) | 1 (3.0) | 1 (9.1) | 26 (7.6) | 5 (4.2) | 7 (7.5) | 5 (9.4) | 0 | 17 (5.9) |
| Data not available | 195 (92.0) | 75 (85.2) | 32 (97.0) | 10 (90.9) | 312 (90.7) | 112 (94.9) | 84 (90.3) | 46 (86.8) | 24 (96.0) | 266 (92.0) |
| t(14;16), n (%) | ||||||||||
| Yes | 7 (3.3) | 4 (4.5) | 1 (3.0) | 0 | 12 (3.5) | 2 (1.7) | 6 (6.5) | 4 (7.5) | 1 (4.0) | 13 (4.5) |
| No | 73 (34.4) | 26 (29.5) | 3 (9.1) | 4 (36.4) | 106 (30.8) | 28 (23.7) | 24 (25.8) | 15 (28.3) | 5 (20.0) | 72 (24.9) |
| Data not available | 82 (38.7) | 37 (42.0) | 14 (42.4) | 5 (45.5) | 138 (40.1) | 61 (51.7) | 42 (45.2) | 26 (49.1) | 12 (48.0) | 141 (48.8) |
| t(4;14), n (%) | ||||||||||
| Yes | 17 (8.0) | 2 (2.3) | 1 (3.0) | 0 | 20 (5.8) | 7 (5.9) | 8 (8.6) | 1 (1.9) | 3 (12.0) | 19 (6.6) |
| No | 151 (71.2) | 64 (72.7) | 21 (63.6) | 6 (54.5) | 242 (70.3) | 74 (62.7) | 57 (61.3) | 36 (67.9) | 12 (48.0) | 179 (61.9) |
| Data not available | 44 (20.8) | 22 (25.0) | 11 (33.3) | 5 (45.5) | 82 (23.8) | 37 (31.4) | 28 (30.1) | 16 (30.2) | 10 (40.0) | 91 (31.5) |
| t(11;14), n (%) | ||||||||||
| Yes | 36 (17.0) | 15 (17.0) | 4 (12.1) | 4 (36.4) | 59 (17.2) | 13 (11.0) | 14 (15.1) | 9 (17.0) | 2 (8.0) | 38 (13.1) |
| No | 101 (47.6) | 43 (48.9) | 13 (39.4) | 2 (18.2) | 159 (46.2) | 47 (39.8) | 34 (36.6) | 26 (49.1) | 9 (36.0) | 116 (40.1) |
| Data not available | 75 (35.4) | 30 (34.1) | 16 (48.5) | 5 (45.5) | 126 (36.6) | 58 (49.2) | 45 (48.4) | 18 (34.0) | 14 (56.0) | 135 (46.7) |
| Hyperdiploidy, n (%) | ||||||||||
| Yes | 14 (6.6) | 7 (8.0) | 1 (3.0) | 1 (9.1) | 23 (6.7) | 6 (5.1) | 11 (11.8) | 6 (11.3) | 0 | 23 (8.0) |
| No | 129 (60.8) | 45 (51.1) | 20 (60.6) | 4 (36.4) | 198 (57.6) | 62 (52.5) | 43 (46.2) | 22 (41.5) | 10 (40.0) | 137 (47.4) |
| Data not available | 69 (32.5) | 36 (40.9) | 12 (36.4) | 6 (54.5) | 123 (35.8) | 50 (42.4) | 39 (41.9) | 25 (47.2) | 15 (60.0) | 129 (44.6) |
ECOG PS Eastern Cooperative Oncology Group performance status, Hb hemoglobin, ISS International Staging System, LLN lower limit of normal, RVd lenalidomide, bortezomib, and dexamethasone.
aIncludes American Indian/Alaskan Native, Asian, Pacific Islander, Other, and Not Specified.
Data cutoff date: August 4, 2021.